Brief: Sprint Bioscience Says Licensed Cancer Drug Program VPS34 To Deciphera Pharmaceuticals

Sprint Bioscience AB

03/08/2021 21:26

Aug 3 (Reuters) - Sprint Bioscience Ab  SPRINT.ST :
    * LICENSED ITS CANCER DRUG PROGRAM VPS34 TO US
PHARMACEUTICAL
COMPANY DECIPHERA PHARMACEUTICALS
    * LICENSE AGREEMENT COVERS EXCLUSIVE GLOBAL RIGHTS TO
PROGRAM
    * AGREEMENT HAS A TOTAL POTENTIAL VALUE OF UP TO USD 277
MILLION
    * ON SIGNING, CO WILL RECEIVE AN UPFRONT PAYMENT OF USD 4
MILLION,
WHICH WILL BE ENTERED INTO ACCOUNTS FOR Q3 OF 2021
    * DECIPHERA WILL NOW TAKE OVER PROGRAM'S CONTINUED
DEVELOPMENT AND
ALL ASSOCIATED COSTS

Source text for Eikon:  ID:nWkr45kJJD 
Further company coverage:  SPRINT.ST 

 ((Reuters.Briefs@thomsonreuters.com;))